NCT03939845Unknown3 期
A Prospective, Randomized, Multicenter Study of Comparison of Transarterial Chemoembolization (TACE) Combination With and Without External- Beam Radiotherapy (EBRT) for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi
Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2019年4月23日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 180
- 试验地点
- 1
- 主要终点
- OS
研究概览
简要总结
The 1-year and 2-year overall survival rate (OS), local control rate (FFLP), disease-free progression time (PFS), and side effects were compared in patients with hepatocellular carcinoma limited to intrahepatic unresectable hepatocellular carcinoma with portal venous thrombosis combined with or without external radiotherapy, providing a basis for the development of relevant guidelines.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •confirmed by pathology or met the clinical diagnostic criteria of hepatocellular carcinoma.
- •after the joint consultation between the interventional department and the radiotherapy department, the patients who were considered to be interventional were considered. Meeting the following criteria: the tumor was confined to the liver (meeting the liver tolerance dose), and was diagnosed as type II or type III portal vein tumor thrombi according to chang's classification criteria, without extrahepatic metastasis. Number of tumors in liver parenchyma: less than or equal to
- •The main portal vein is not completely blocked or the compensatory collateral vessels of the portal vein are abundant although it is completely blocked.
- •patients who meet all the following criteria: Child-Pugh score ≤7, PLT>30×109/L, WBC>3×10^9/L/ANC>1.5×10^9/L,Hb>90g/L, Cr<2.0mg/dL.
- •ECOG score 0-2 points.
- •estimated survival time > 3 months.
- •sign the informed consent.
排除标准
- •patients with the following condition: the number of intrahepatic tumors >3 or total tumor diameter>15cm.
- •patients with signs of extrahepatic metastasis, including but not limited to inferior vena cava carcinoma thrombus, bone metastasis, brain metastasis or regional lymph node metastasis.
- •patients with West Haven standard grade III/IV hepatic encephalopathy or ascites.
- •patients with a history of malignancy other than primary HCC, except for cutaneous squamous cell carcinoma or basal cell carcinoma.
- •patients with a history of upper abdominal radiotherapy.
- •in the radiotherapy plan, patients who failed to follow the radiation dose limit of important organs, including those whose normal liver tissue was less than 700 ml in the radiotherapy plan.
- •screening patients who have received other study drugs within 4 weeks prior to the start of the visit.
- •screening: patients who had received treatment for other local or systemic hepatocellular carcinoma within 4 weeks before the visit.
- •patients with significant concurrent diseases.
- •lactating or pregnant female patients.
研究组 & 干预措施
TACE+RT
Experimental
干预措施: RT (Radiation)
TACE+RT
Experimental
干预措施: TACE (Procedure)
TACE
Active Comparator
干预措施: TACE (Procedure)
结局指标
主要结局
OS
时间窗: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
overall survival
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With GlioblastomaGlioblastomaNCT04485949Imvax99
尚未招募
3 期
Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRTRecurrent Nasopharyngeal CarcinomaNCT04215510Eye & ENT Hospital of Fudan University286
招募中
不适用
Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cmHepatocellular CancerMicrowave AblationMicrowave Spherical AblationPrognosisNCT05361538Tianjin Third Central Hospital60
招募中
3 期
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial CancerAdvanced or Metastatic Urothelium CancerNCT05754853Shanghai Miracogen Inc.290
已完成
2 期
Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced HepatocarcinomaAdvanced HepatocarcinomaNCT01418729Hospital Donostia216